Tedros Adhanom Ghebreyesus, World Health Organization

Gaps in surveillance, testing, sequencing, and vaccination for COVID-19 could create the perfect storm for a new variant.

brain scan

Athira Pharma’s experimental Alzheimer’s therapy, fosgonimeton, continues to show signs of being able to improve cognition and function in patients.


Adding to yesterday’s announcement of a $1.26 billion investment in Dublin, the company said it plans to match that investment to expand its Puurs, Belgium manufacturing site.


“We believe that subcutaneous formulation has the potential to be novel, non-obvious and useful, which means we would get a new patent for it,” according to Merck CFO Caroline Litchfield.


While acquiring Horizon would add a mixed portfolio of specialty drugs to Sanofi’s roster, it would not address the French company’s need to develop its drug pipeline and improve its productivity from research and development, analysts say.


The company was seeking approval of omburtamab to treat a rare form of nerve cancer in pediatric patients. The FDA’s decision follows a unanimous vote in October against the drug to treat neuroblastoma due to insufficient evidence that it improves overall survival.

The drug will be sold under the brand Rezlidhia and indicated for treating acute myeloid leukemia in patients with a susceptible genetic mutation.

Sunny Balwani, Theranos

Balwani countered that probation, meaning no prison time, is sufficient, citing his own investment losses in a company once valued at $9 billion, and saying he never sought the “fame or media attention” that Holmes attracted as Theranos’ public face.

Elon Musk, Neuralink

The company is developing brain chip interfaces that it says could help disabled patients to move and communicate again, with Musk adding it will also target restoring vision.


PictorLabs emerged from stealth mode Thursday with $15 million to advance its AI-powered virtual staining platform that researchers hope will “reimagine the future” of histopathology.